



Performing your original search, **pubmed mast cell activation disorder**, in PubMed Central will retrieve **16** records.

J Hematol Oncol. 2011; 4: 10.

PMCID: PMC3069946

Published online 2011 March 22. doi: 10.1186/1756-8722-4-10

Copyright ©2011 Molderings et al; licensee BioMed Central Ltd.

Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options

Gerhard J Molderings,¹ Stefan Brettner,² Jürgen Homann,³ and Lawrence B Afrin⁴

¹Institute of Human Genetics, University Hospital of Bonn, Sigmund-Freud-Str. 25, D-53127 Bonn, Germany

²Department of Oncology, Hematology and Palliative Care, Kreiskrankenhaus Waldbröl, Dr.-Goldenburgen-Str. 10, D-51545 Waldbröl, Germany

³Department of Internal Medicine, Evangelische Kliniken Bonn, Waldkrankenhaus, Waldstrasse 73, D-53177 Bonn, Germany

⁴Division of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina, USA

✉ Corresponding author.

Gerhard J Molderings: molderings@uni-bonn.de; Stefan Brettner: dr.brettner@khh-waldbroel.de; Jürgen Homann: Juergen.Homann@ev-waldkrankenhaus.de; Lawrence B Afrin: afrinl@muscc.edu

Received January 20, 2011; Accepted March 22, 2011.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Mast cell activation disease comprises disorders characterized by accumulation of genetically altered mast cells and/or abnormal release of these cells' mediators, affecting functions in potentially every organ system, often without causing abnormalities in routine laboratory or radiologic testing. In most cases of mast cell activation disease, diagnosis is possible by relatively non-invasive investigation. Effective therapy often consists simply of antihistamines and mast cell membrane-stabilising compounds supplemented with medications targeted at specific symptoms and complications. Mast cell activation disease is now appreciated to likely be considerably prevalent and thus should be considered routinely in the differential diagnosis of patients with chronic multisystem polymorbidity or patients in whom a definitively diagnosed major illness does not well account for the entirety of the patient's presentation.

Introduction

The term *mast cell activation disease* (MCAD) denotes a collection of disorders characterized by (1) accumulation of pathological mast cells in potentially any or all organs and tissues and/or (2) aberrant release of variable subsets of mast cell mediators. A classification has been proposed which differentiates several types and subclasses of MCAD (Table 1). The traditionally recognized subclass termed *systemic mastocytosis* (SM) includes disorders characterized by certain pathological immunohistochemical and mutational findings (the WHO criteria; Table 2; [1,2]) which are divided into several subtypes (Table 1). On the other hand, *mast cell activation syndrome* (MCAS) presents a complex clinical picture of multiple mast cell mediator-induced symptoms, failure to meet the WHO criteria for diagnosis of SM, and exclusion of relevant differential diagnoses [1,3-5]. Symptoms observed in patients with MCAS are little, if any, different from those seen in patients with SM [6-8]. Patients present variable and often fluctuating patterns of symptoms (Table 3; [9-15]) which depend on the tissue responses to mast cell mediators released both spontaneously and in response to trigger stimuli.

Table 1

Table 1 Classification of mast cell activation disease (modified from [2-4]).	
Mast cell activation disease (MCAD)	
Mast cell activation syndrome (MCAS)	
Systemic mastocytosis (SM) defined by the WHO criteria	<ul style="list-style-type: none"> • Incident systemic mastocytosis • Isolated bone marrow mastocytosis • Smoldering systemic mastocytosis • Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease • Aggressive systemic mastocytosis
Mast cell leukemia (MCL)	

Classification of mast cell activation disease (modified from [2-4]).

Table 2 Criteria proposed to define mast cell activation disease (for references, see text).	
Criteria to define mast cell activation syndrome	WHO criteria to define systemic mastocytosis
Major criteria	Major criterion
1. Multifocal or disseminated dense infiltrates of mast cells in bone marrow biopsies and/or in sections of other extracutaneous organ(s) (e.g., gastrointestinal tract biopsies, CD117-, tryptase- and CD25-stained)	Multifocal dense infiltrates of mast cells (>15 mast cells in aggregates) in bone marrow biopsies and/or in sections of other extracutaneous organ(s) (CD117-, tryptase- and CD25-stained)
2. Unique constellation of clinical complaints as a result of a pathologically increased mast cell activity (mast cell mediator release syndrome)	
Minor criteria	Minor criteria
1. Mast cells in bone marrow or other extracutaneous organ(s) show an	1. Mast cells in bone marrow or other extracutaneous organ(s) show an

Table 2

Criteria proposed to define mast cell activation disease (for references, see text).

Table 3 Frequent signs and clinical symptoms ascribed to episodic unregulated release of mast cell mediators (modified from [12]; further references therein; an exhaustive survey is given in [50]).	
Signs and Symptoms	
Abdominal	abdominal pain, intestinal cramping and bloating, diarrhea and/or constipation, nausea, non-cardiac chest pain, Helicobacter pylori-negative gastritis, malabsorption
Oropharyngeal	burning pain, epiphora
Respiratory	cough, asthma-like symptoms, dyspnea, rhinitis, sinusitis
Ophthalmologic	conjunctivitis, difficulty in focusing
Melanin	erythromelanotic, brownish-black macules, absence of hair

Table 3

Frequent signs and clinical symptoms ascribed to episodic unregulated release of mast cell mediators (modified from [12]; further references therein; an exhaustive survey is given in [50]).

A rare variant of MCAD is mast cell leukemia (MCL; Table 1). This aggressive mast cell neoplasm is defined by increased numbers of mast cells in bone marrow smears ($\geq 20\%$) and by circulating mast cells (reviewed in [2]). Patients typically suffer from rapidly progressive organopathy involving the liver, bone marrow and other organs. The bone marrow typically shows a diffuse, dense infiltration with mast cells. In typical MCL, mast cells account for more than 10% of blood leukocytes. In a smaller group of patients, pancytopenia occurs and mast cells account for less than 10% (aleukemic variant of MCL). The prognosis in MCL is poor. Most patients survive less than 1 year and respond poorly to cytoreductive drugs or chemotherapy.

Mast cell activation disease in general has long been thought to be rare. However, although SM and MCL as defined by the WHO criteria are truly rare, recent findings suggest MCAS is a fairly common disorder. Evidence has been presented for a causal involvement of pathologically active mast cells not only in the pathogenesis of SM and MCAS but also in the etiology of idiopathic anaphylaxis [16-18], interstitial cystitis [19], some subsets of fibromyalgia [20,21] and some subsets of irritable bowel syndrome [22-24].

Pathogenesis

Mutations in kinases (particularly in the tyrosine kinase Kit) and in enzymes and receptors (JAK2, PDGFR α , RASGRP4, Src-kinases, c-Cbl-encoded E3 ligase, histamine H4 receptor) which are crucially involved in the regulation of mast cell activity have been identified as necessary to establish a clonal mast cell population, but other abnormalities yet to be determined must be added for the development of a clinically symptomatic disease ([7,8,25,26]; further references therein). The observations that the same KIT mutation (e.g. D816V) can be associated with both good prognosis as well as progression to advanced disease [27] and that the D816V mutation has also been detected in healthy subjects [28] highlight the potential role of other factors in determining the progression/outcome of the disease. Recent findings suggest that the immunohistochemical and morphological

alterations which constitute the WHO criteria for SM (formation of mast cell clusters; spindle-shaped morphology of mast cells; expression of CD25 on mast cells; Table 2) are causally related to and specific for the occurrence of a mutation in codon 816 of tyrosine kinase Kit in the affected mast cells [6,29-31]. Another aspect that limits the diagnostic value of this mutation is that during progression of SM the Kit mutant D816V may disappear ([32]; own unpublished observation). Taken together, the recent genetic findings suggest that the clinically different subtypes of MCAD (encompassing SM, MCL, and MCAS) should be more accurately regarded as varying presentations of a common generic root process of mast cell dysfunction than as distinct diseases [4,7,8,11].

Clinical diagnostics

MCAD is first suspected on clinical grounds, based on recognition of compatible mast cell mediator-related symptoms and, in some, identification of typical skin lesions. The clinical presentation of MCAD is very diverse, since due to both the widespread distribution of mast cells and the great heterogeneity of aberrant mediator expression patterns, symptoms can occur in virtually all organs and tissues (Table 3). Moreover, symptoms often occur in a temporally staggered fashion, waxing and waning over years to decades. Symptoms often initially manifest during adolescence or even childhood or infancy but are recognized only in retrospect as MCAD-related. Clinical features and courses vary greatly and range from very indolent with normal life expectancy to highly aggressive with reduced survival times. Physical examination should include inspection for a large assortment of types of skin lesions, testing for dermatographism (Darier's sign), and palpating for hepatosplenomegaly and lymphadenopathy. A diagnostic algorithm is shown in Figure 1. Recognition of a mast cell mediator release syndrome, i.e. a pattern of symptoms caused by the unregulated increased release of mediators from mast cells, can be aided by use of a validated checklist [2,11,12,33] which lists the complaint complexes to be considered. In addition to the detection of the characteristic clinical constellation of findings, it must be investigated whether levels of the mast cell-specific mediators tryptase, histamine, and heparin are elevated in the blood, whether the excretion of the histamine metabolite methylhistamine into the urine is increased, and whether mast cell activity-related eosinophilia, basophilia or monocytosis in the blood can be observed. Other useful markers fairly specific to mast cells include serum chromogranin A (in the absence of cardiac and renal failure, neuroendocrine cancer, and proton pump inhibitor use) and serum and urinary leukotriene and prostaglandin isoforms (e.g., leukotriene E₄, prostaglandin D₂, and prostaglandin 9 α ,11 β PGF₂). Together with a characteristic clinical presentation, abnormal markers can be of diagnostic, therapeutic and prognostic relevance. However, it remains unsettled whether demonstration of an elevation of mast cell activity markers is absolutely necessary for diagnosis of MCAD because (1) many conditions (e.g., degrading enzymes, complexing molecules, tissue pH) may attenuate or impede spill-over of exocytosed mediators from tissues into the blood, (2) only a handful of the more than 60 releasable mast cell mediators can be detected by routine commercial techniques, and (3) mediator release syndrome may be due to an amplification cascade of basophil, eosinophil, and general leukocyte activation induced by liberation of only a few mast cell mediators [34] which, again, may not be detectable by present techniques.




Figure 1
Diagnostic algorithm.

When relevant differential diagnoses of a mast cell activation disease (Table 4) which may present mast cell mediator-induced symptoms by activation of normal mast cells (e.g., allergy) or as result of non-mast-cell-specific expression of mediators (e.g., neuroendocrine cancer) are excluded, the cause of the mast cell mediator release syndrome must lie in the uncontrolled increase in activity of pathologically altered mast cells. Patients with most types of MCAD often initially enjoy symptom-free intervals interspersed amongst symptomatic periods. Over time, symptom-free intervals shorten, and finally symptoms become chronic with intensity which fluctuates but with an

overall trend toward steadily increasing intensity. Following the proposed revised diagnostic criteria (Table 2; [3-5,9,35]), MCAD is diagnosed if either both major criteria or one major criterion and at least one minor criterion are met. After clinical diagnosis, a bone marrow biopsy is usually recommended because based on current information it cannot be predicted whether the genetic alterations inducing pathological mast cell activity in affected mast cells have not also induced disturbances in hematopoietic non-mast cell lineages. SM due to codon 816 mutations has been shown to be associated with myeloid neoplasms (and, less frequently, with B-cell neoplasms) frequently enough to warrant routine marrow biopsy when SM is suspected (e.g., serum tryptase elevation per the WHO criteria, frequent unprovoked anaphylactoid events). The frequency of discovery of associated hematologic neoplasms on marrow biopsy at the time of diagnosis of MCAS remains unclear but in our experience appears very low. However, a byproduct of marrow biopsy is that immunohistochemical analysis of the specimen may permit the classification of the mast cell activation disease as SM defined by the WHO criteria or as MCAS (Table 2). In this context, it has to be considered that due to the typically patchy distribution of mast cell infiltration in the bones a single marrow biopsy fails to find systemic mastocytosis in the marrow approximately one-sixth of the time [36].

Table 4 Diseases which should be considered as differential diagnoses of mast cell activation disease, since they may mimick or may be associated with mast cell activation (diagnostic procedure of choice in parentheses).	
Endocrinologic disorders	Diabetes mellitus (laboratory determination) Pancreatic endocrine tumours (gastrinoma, insulinoma, glucagonoma, somatostatinoma, VIPoma; laboratory determination, medical history) Porphyrria (laboratory determination) Disorders of the thyroid gland (laboratory determination) Morbus Fabry (clinical picture, molecular genetic investigation)
Gastrointestinal disorders	Helicobacter positive gastritis (gastroscopy, biopsy) Infectious enteritis (stool examination) Eosinophilic gastroenteritis (endoscopy, biopsy) Parasitic infections (stool examination)

Table 4

Diseases which should be considered as differential diagnoses of mast cell activation disease, since they may mimick or may be associated with mast cell activation (diagnostic procedure of choice in parentheses).

An aggressive course of MCAD is characterized and defined by organopathy caused by pathologic infiltration of various organs by neoplastic mast cells inducing an impairment of organ function. Organopathy due to mast cell infiltration is indicated by findings termed *C-findings*: (1) significant cytopenia(s); (2) hepatomegaly with impairment of liver function due to mast cell infiltration, often with ascites; (3) splenomegaly with hypersplenism; (4) malabsorption with hypoalbuminemia and weight loss; (5) life-threatening impairment of organ function in other organ systems; (6) osteolyses and/or severe osteoporosis with pathologic fractures. Urticaria pigmentosa-like skin lesions are usually absent. In contrast to MCL, the bone marrow smear shows fewer than 20% mast cells (reviewed in [2]). Mast cell infiltration with organomegaly but without end organ dysfunction (hepatomegaly, splenomegaly, lymphadenopathy, bone marrow alterations) is a *B-finding* and may occur in a subvariant of SM (smoldering SM) with high mast cell burden.

Treatment of mast cell activation diseases

The cornerstone of therapy is avoidance of identifiable triggers for mast cell degranulation such as animal venoms, extremes of temperature, mechanical irritation, alcohol, or medications (e.g., aspirin, radiocontrast agents, certain anesthetic agents). Individual patients may have variable tolerance patterns and avoidance lists, but it also is not uncommon to have no identifiable, reliable triggers.

Drug treatment of MCAD patients is highly individualized. Curative therapies are not available, and each MCAD patient should be treated in accordance with his symptoms and complications. Irrespective of the specific clinical presentation of MCAD, evidence-based therapy consists of trigger avoidance, antihistamines, and mast cell membrane-stabilising compounds (basic therapy, Table 5) supplemented as needed by medications targeting individual mast cell mediator-induced symptoms or complications (symptomatic therapy, Table 5). First hints of success with any given therapy are usually seen within 4 weeks once suitable dosing has been achieved. Multiple simultaneous changes in the medication regimen are discouraged since such can confound identification of the specific therapy responsible for a given improvement (or deterioration). Ineffective or harmful agents should be

stopped promptly. If symptoms are resistant to therapy, as a next therapeutic step toward reducing mast cell activity and thereby decreasing mediator release, treatment with prednisone, ciclosporine (cyclosporine A), low dose methotrexate or azathioprine can be considered. Recently, anti-IgE treatment with the humanized murine monoclonal antibody omalizumab has alleviated high intensity symptoms of MCAD [37]. Since treatment with omalizumab has an acceptable risk-benefit profile, it should be considered in cases of MCAD resistant to evidence-based therapy. Recently, molecularly targeted therapy by tyrosine kinase inhibitors such as imatinib mesylate, dasatinib and midostaurin has been investigated. As with all drugs used in therapy of MCAD, their therapeutic success seems to be strongly dependent on the individual patient. In formal studies in SM patients, although the kinase inhibitors reduced mast cell burden as reflected by histological normalization in bone marrow and improved laboratory surrogate markers, at best only partial improvement of mediator-related symptoms was achieved [38-41]. However, in some case reports, imatinib and dasatinib have been significantly effective at relieving symptoms. In spite of potential significant adverse effects of these drugs, a therapeutic trial may be justified in individual cases at an early stage. Given that PI3K/AKT/mTOR is one of the downstream signalling pathways upregulated by activated Kit, in theory mTOR inhibitors (e.g., sirolimus, temsirolimus, everolimus) may have utility in MCAD, but to date the one trial of this notion (everolimus in SM) showed no significant clinical activity [42].

Table 5 Treatment options for mast cell activation disease.	
Basic therapy (continuous oral combination therapy to reduce mast cell activity)	<ul style="list-style-type: none"> • H₁ histamine receptor antagonist (to block activating H₁ histamine receptors on mast cells; to antagonize H₁ histamine receptor-mediated symptoms) • H₂ histamine receptor antagonist (to block activating H₂ histamine receptors on mast cells; to antagonize H₂ histamine receptor-mediated symptoms) • Cromolyn sodium (stabilising mast cells) • Slow-release Vitamin C (increased degradation of histamine; inhibition of mast cell degranulation; not more than 750 mg/day) • If necessary, ketotifen to stabilise mast cells and to block activating H₁ histamine receptors on mast cells
Symptomatic treatment options (orally as needed)	<ul style="list-style-type: none"> • Headache → paracetamol, metamizole, Acetaminophen • Diarrhea → loperamide, cytotec, montelukast, 5-HT₂ receptor inhibitors (eg, ondansetron); incremental doses (50-250 mg/day; extreme caution because of the possibility to reduce mast cell degranulation) of acetylsalicylic acid (in-steps)

Table 5

Treatment options for mast cell activation disease.

A difficult situation is the occurrence of life-threatening anaphylaxis in patients with MCAD. If anaphylaxis is provoked by a known allergen, especially hymenoptera venom, immunotherapy should be considered with recognition of potential risks [43-45]. In case of repeated life-threatening anaphylactoid episodes, the self-administration of epinephrine on demand has been recommended as an appropriate approach.

In patients with high-grade variants of MCAD (presence of C-findings) and a progressive clinical course, cytoreductive drugs are recommended and are prescribed together with anti-mediator-type drugs [46,47]. Potential therapeutic options are interferon- α and 2-chlorodeoxyadenosine (2-CdA, cladribine). Interferon- α is frequently combined with prednisone and is commonly used as first-line cytoreductive therapy for aggressive SM. It ameliorates SM-related organopathy in a proportion of cases but is associated with considerable adverse effects (e.g., flu-like symptoms, myelosuppression, depression, hypothyroidism), which may limit its use in MCAD [48,49]. PEGylated interferon- α has been shown to be as efficacious as, and less toxic than the non-PEGylated form in some chronic myeloproliferative diseases, but it has not been specifically studied in MCAD. 2-Chlorodeoxyadenosine (2-CdA) is generally reserved for last choice treatment of patients with aggressive SM who are either refractory or intolerant to interferon- α . Potential toxicities of 2-CdA include significant and potentially prolonged myelosuppression and lymphopenia with increased risk of opportunistic infections. Patients who fail interferon- α and 2-CdA therapy are candidates for experimental drugs. However, such therapeutic maneuvers and their potential beneficial effects have to be balanced against the long-term risk and serious side effects of these therapies (often immunosuppressive or/and mutagenic). Polychemotherapy including intensive induction regimens of the kind used in treating acute myeloid leukemia, as well as high-dose therapy with stem cell rescue, represent investigational approaches restricted to rare, selected patients. A variety of other agents have been reported to have in-vitro activity against at least some MCAD-associated mutations [3] and may have a future role in the treatment of this disease.

No tools yet exist to predict which specific therapeutic regimen will be optimal for the individual MCAD patient. However, especially in non-aggressive disease (comprising the great majority of patients), at least partial improvement is usually attainable with one regimen or another, and thus the practitioner is obligated to persist with therapeutic trials until no options remain. Finally, although clinical trials in MCAD are rare, enrolment in such must be a priority.

Conclusions

MCAD comprises disorders affecting functions in potentially every organ system by abnormal release of mediators from and/or accumulation of genetically altered mast cells. There is evidence that MCAD is a disorder with considerable prevalence and thus should be considered routinely in the differential diagnosis of patients with chronic multisystem polymorbidity of unknown cause. In most cases of MCAD, diagnosis is possible by relatively non-invasive investigation. Effective therapy often consists simply of antihistamines and mast cell membrane-stabilising compounds supplemented with medications targeted at specific symptoms and complications.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

All authors have equally contributed to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Publication of this article was supported by the *B.Braun-Stiftung* (Germany) and the *Förderclub Mastzellforschung e. V.* (Germany).

References

1. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nuñez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW, Bennett JM. Diagnostic criteria and classification of mastocytosis: a consensus proposal. *Leuk Res.* 2001;**25**:603–625. doi: 10.1016/S0145-2126(01)00038-8. [PubMed] [Cross Ref]
2. Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluijn-Nelemans HC, Hamdy NA, Lortholary O, Robyn J, van Doormaal J, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. *Eur J Clin Invest.* 2007;**37**:435–453. doi: 10.1111/j.1365-2362.2007.01807.x. [PubMed] [Cross Ref]
3. Homann J, Kolck UW, Ehnes A, Frieling T, Raitheil M, Molderings GJ. Systemic mastocytosis - definition of an internal disease. *Med Klin (Munich)* 2010;**105**:544–553. doi: 10.1007/s00063-010-1093-8. [PubMed] [Cross Ref]
4. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed diagnostic criteria. *J Allergy Clin Immunol.* 2010;**126**:1099–1104. doi: 10.1016/j.jaci.2010.08.035. [PubMed] [Cross Ref]
5. Hamilton MJ, Castells M, Greenberger NJ. Mast cell activation syndrome - a newly recognized cause of recurrent acute abdominal pain. *Gastroenterology.* 2010;**138**(Suppl 1):S89.
6. Alvarez-Twose I, González de Olano D, Sánchez-Muñoz L, Matito A, Esteban-López MI, Vega A, Mateo MB, Alonso Díaz de Durana MD, de la Hoz B, Del Pozo Gil MD, Caballero T, Rosado A, Sánchez Matas I, Teodósio C, Jara-Acevedo M, Mollejo M, García-Montero A, Orfao A, Escribano L. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. *J Allergy Clin Immunol.* 2010;**125**:1269–1278. doi: 10.1016/j.jaci.2010.02.019. [PubMed] [Cross Ref]
7. Molderings GJ, Kolck UW, Scheurien C, Brüß M, Homann J, von Kügelgen I. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. *Scand J Gastroenterol.* 2007;**42**:1045–1053. doi: 10.1080/00365520701245744. [PubMed] [Cross Ref]

8. Molderings GJ, Meis K, Kolck UW, Homann J, Frieling T. Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects. *Immunogenetics*. 2010;**62**:721–727. doi: 10.1007/s00251-010-0474-8. [PubMed] [Cross Ref]
9. Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and the Women's Hospital. *Invest Dermatol*. 1991;**96**:5S–14S. doi: 10.1111/1523-1747.ep12468899. [Cross Ref]
10. Castells M. Mast cell mediators in allergic inflammation and mastocytosis. *Immunol Allergy Clin North Am*. 2006;**26**:465–485. doi: 10.1016/j.jaci.2006.05.005. [PubMed] [Cross Ref]
11. Hermine O, Lortholary O, Leventhal PS, Catteau A, Soppelsa F, Baude C, Cohen-Akenine A, Palmérini F, Hanssens K, Yang Y, Sobol H, Fraytag S, Ghez D, Suarez F, Barete S, Casassus P, Sans B, Arock M, Kinet JP, Dubreuil P, Moussy A. Case-control cohort study of patients' perceptions of disability in mastocytosis. *PLoS ONE*. 2008;**3**:e2266. doi: 10.1371/journal.pone.0002266. [PMC free article] [PubMed] [Cross Ref]
12. Alfter K, von Kügelgen I, Haenisch B, Frieling T, Hülsdonk A, Haars U, Rolfs A, Noe G, Kolck UW, Homann J, Molderings GJ. New aspects of liver abnormalities as part of the systemic mast cell activation syndrome. *Liver Int*. 2009;**29**:181–186. doi: 10.1111/j.1478-3231.2008.01839.x. [PubMed] [Cross Ref]
13. Escribano L, Alvarez-Twose I, Sánchez-Muñoz L, García-Montero A, Núñez R, Almeida J, Jara-Acevedo M, Teodósio C, García-Cosío M, Bellas C, Orfao A. Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. *J Allergy Clin Immunol*. 2009;**124**:514–521. doi: 10.1016/j.jaci.2009.05.003. [PubMed] [Cross Ref]
14. Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. *Am J Hematol*. 2009;**84**:790–794. doi: 10.1002/ajh.21561. [PubMed] [Cross Ref]
15. Lundequist A, Pejler G. Biological implications of preformed mast cell mediators. *Cell Mol Life Sci*. 2011;**68**:965–975. doi: 10.1007/s00018-010-0587-0. [PubMed] [Cross Ref]
16. Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P, Metcalfe DD. Demonstration of an aberrant mast cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. *Blood*. 2007;**110**:2331–2333. doi: 10.1182/blood-2006-06-028100. [PMC free article] [PubMed] [Cross Ref]
17. Gonzalez de Olano D, de la Hoz Caballer B, Nunez Lopez R, Sanchez Munoz L, Cuevas Agustin M, Dieguez MC, Alvarez Twose I, Castells MC, Escribano Mora L. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA) *Clin Exp Allergy*. 2007;**37**:1547–1555. [PubMed]
18. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. *Allergy*. 2008;**63**:226–232. doi: 10.1111/j.1398-9995.2007.01569.x. [PubMed] [Cross Ref]
19. Sant GR, Kempuraj D, Marchand JE, Theoharides TC. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. *Urology*. 2007;**69**(4 Suppl):34–40. doi: 10.1016/j.urology.2006.08.1109. [PubMed] [Cross Ref]
20. Enestrom S, Bengtsson A, Frodin T. Dermal IgG deposits and increase of mast cells in patients with fibromyalgia - relevant findings or epiphenomena? *Scand J Rheumatol*. 1997;**26**:308–313. doi: 10.3109/03009749709105321. [PubMed] [Cross Ref]
21. Lucas HJ, Brauch CM, Settas L, Theoharides TC. Fibromyalgia - new concepts of pathogenesis and treatment. *Int J Immunopathol Pharmacol*. 2006;**19**:5–9. [PubMed]
22. Kolck UW. Investigations on the pathogenesis of the systemic mast cell activation syndrome and its impact on heart function. *Bonn, University, medical thesis*. 2009. <http://hss.ulb.uni-bonn.de/2009/1906/1906.htm> URN:nbn:de:hbz:5N-19064.
23. Nickel JC, Tripp DA, Pontari MA, Moldwin RM, Mayer R, Carr LK, Doggweiler R, Yang CC, Whitcomb D, Mishra N, Nordling J. Phenotypic associations between interstitial cystitis/painful bladder syndrome and irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome: a case control study. *J Urology*. 2009;**181**(Suppl):19. doi: 10.1016/S0022-5347(09)60067-7. [Cross Ref]
24. Frieling T, Meis K, Kolck UW, Homann J, Hülsdonk A, Haars U, Hertfelder H-J, Oldenburg J, Seidel H, Molderings GJ. Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome. *Z Gastroenterol*. 2011;**49**:191–194. doi: 10.1055/s-0029-1245707. [PubMed] [Cross Ref]
25. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L. REMA: Recent advances in the understanding of mastocytosis: the role of KIT mutations. *Br J Haematol*. 2007;**138**:12–30. doi: 10.1111/j.1365-2141.2007.06619.x. [PubMed] [Cross Ref]

26. Bodemer C, Hermine O, Palmérini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, Hadj-Rabia S, Nasca L, Georgin-Lavialle S, Cohen-Akenine A, Launay JM, Barete S, Feger F, Arock M, Cateau B, Sans B, Stalder JF, Skowron F, Thomas L, Lorette G, Plantin P, Bordignon P, Lortholary O, de Prost Y, Moussy A, Sobol H, Dubreuil P. Pediatric mastocytosis is a clonal disease associated with D(816)V and other activating c-KIT mutations. *J Invest Dermatol*. 2010;**130**:804–815. doi: 10.1038/jid.2009.281. [PubMed] [Cross Ref]
27. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, Aldanondo I, Sanchez L, Dominguez M, Botana LM, Sanchez-Jimenez F, Sotlar K, Almeida J, Escribano L, Orfao A. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. *Blood*. 2006;**108**:2366–2372. doi: 10.1182/blood-2006-04-015545. [PubMed] [Cross Ref]
28. Lawley W, Hird H, Mallinder P, McKenna S, Hargadon B, Murray A, Bradding P. Detection of an activating c-kit mutation by real-time PCR in patients with anaphylaxis. *Mutation Res*. 2005;**572**:1–13. doi: 10.1016/j.mrfmmm.2004.08.015. [PubMed] [Cross Ref]
29. Mayerhofer M, Gleixner KV, Hoelbl A, Florian S, Hoermann G, Aichberger KJ, Bilban M, Esterbauer H, Krauth MT, Sperr WR, Longley JB, Kralovics R, Moriggl R, Zappulla J, Liblau RS, Schwarzwinger I, Sexl V, Sillaber C, Valent P. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. *J Immunol*. 2008;**180**:5466–5476. [PMC free article] [PubMed]
30. Teodosio C, García-Montero AC, Jara-Acevedo M, Sánchez-Muñoz L, Alvarez-Twose I, Núñez R, Schwartz LB, Walls AF, Escribano L, Orfao A. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. *J Allergy Clin Immunol*. 2010;**125**:719–726. doi: 10.1016/j.jaci.2009.10.020. [PubMed] [Cross Ref]
31. Yang Y, Létard S, Borge L. Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. *Blood*. 2010;**116**:1114–1123. doi: 10.1182/blood-2009-06-226027. [PubMed] [Cross Ref]
32. Gotlib J, Berubé C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutré SE. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. *Blood*. 2005;**106**:2865–2870. doi: 10.1182/blood-2005-04-1568. [PMC free article] [PubMed] [Cross Ref]
33. Molderings GJ, Kolck U, Scheurle C, Brüß M, Frieling T, Raithel M, Homann J. Systemic mast cell disease with gastrointestinal symptoms - a diagnostic questionnaire. *Dtsch Med Wochenschr*. 2006;**131**:2095–2100. doi: 10.1055/s-2006-951337. [PubMed] [Cross Ref]
34. Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitos D. Differential release of mast cell mediators and the pathogenesis of inflammation. *Immunol Rev*. 2007;**217**:65–78. doi: 10.1111/j.1600-065X.2007.00519.x. [PubMed] [Cross Ref]
35. Roberts LJ, Oates JA. Biochemical diagnosis of systemic mast cell disorders. *J Invest Dermatol*. 1991;**96**(3 Suppl):19S–24S. doi: 10.1111/1523-1747.ep12468945. [Cross Ref]
36. Butterfield JH, Li C-Y. Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient? *Am J Clin Path*. 2004;**121**:264–267. doi: 10.1309/2EWQKN00PG02JKY0. [PubMed] [Cross Ref]
37. Molderings GJ, Raithel M, Kratz F, Azemar M, Haenisch B, Harzer S, Homann J. Omalizumab treatment of systemic mast cell activation disease: experiences from four cases. *Intern Med*. 2011;**50**:1–5. doi: 10.2169/internalmedicine.50.4640. [PubMed] [Cross Ref]
38. Droogendijk HJ, Kluijn-Nelemans HJC, van Doormaal JJ, Oranje AR, van de Loosdrecht AA, van Daele PLA. Imatinib mesylate in the treatment of systemic mastocytosis - A phase II trial. *Cancer*. 2006;**107**:345–351. doi: 10.1002/cncr.21996. [PubMed] [Cross Ref]
39. Gotlib J, George TI, Corless C, Linder A, Ruddell A, Akin C, DeAngelo DJ, Kepten I, Lanza C, Heinemann H, Yin O, Gallagher N, Graubert T. The Kit tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): interim results of a phase II trial. *Blood*. 2008;**110**:1039A.
40. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshoury T, Thomas D, Kantarjian H. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. *Clin Cancer Res*. 2008;**14**:3906–3915. doi: 10.1158/1078-0432.CCR-08-0366. [PubMed] [Cross Ref]
41. Vega-Ruiz A, Cortes JE, Sever M, Manshoury T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. *Leuk Res*. 2009;**33**:1481–1484. doi: 10.1016/j.leukres.2008.12.020. [PubMed] [Cross Ref]
42. Parikh SA, Kantarjian HM, Richie MA, Cortes JE, Verstovsek S. Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. *Leuk Lymph*. 2010;**51**:269–274. doi: 10.3109/10428190903486220.

[Cross Ref]

43. de Olano DG, Twose IA, Esteban López MI, Muñoz LS, Alonso Díaz de Durana MD, Castro AV, Montero AG, González-Mancebo E, González TB, Herrero Gil MD, Fernández-Rivas M, Orfao A, de la Hoz Caballer B, Castells MC, Mora LE. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. *J Allergy Clin Immunol*. 2008;**121**:519–526. doi: 10.1016/j.jaci.2007.11.010. [PubMed] [Cross Ref]
44. Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, Aberer W, Birnbaum J, Bodzenta-Lukaszyk A, Bonifazi F, Bucher C, Campi P, Darsow U, Egger C, Haeberli G, Hawranek T, Körner M, Kucharewicz I, Küchenhoff H, Lang R, Quercia O, Reider N, Severino M, Sticherling M, Sturm GJ, Wüthrich B. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase—a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. *J Allergy Clin Immunol*. 2009;**124**:1047–1054. [PubMed]
45. Bonadonna P, Zanotti R, Müller U. Mastocytosis and insect venom allergy. *Curr Opin Allergy Clin Immunol*. 2010;**10**:347–353. doi: 10.1097/ACI.0b013e32833b280c. [PubMed] [Cross Ref]
46. Valent P, Sperr WR, Akin C. How I treat patients with advanced systemic mastocytosis. *Blood*. 2010;**116**:5812–5817. doi: 10.1182/blood-2010-08-292144. [PubMed] [Cross Ref]
47. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, McClure RF, Li CY, Pardanani A. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. *Blood*. 2009;**113**:5727–5736. doi: 10.1182/blood-2009-02-205237. [PubMed] [Cross Ref]
48. Simon J, Lortholary O, Caillat-Vigneron N, Raphael M, Martin A, Briere J, Barete S, Hermine O, Casassus P. Interest of interferon alpha in systemic mastocytosis. The french experience and review of the literature. *Pathol Biol*. 2004;**52**:294–299. doi: 10.1016/j.patbio.2004.04.012. [PubMed] [Cross Ref]
49. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. *Acta haematol*. 2005;**114**:26–40. doi: 10.1159/000085560. [PubMed] [Cross Ref]
50. Afrin LB. Polycythemia from mast cell activation disorder: lessons from incongruence of symptoms vs. test results. *Am J Med Sci*. 2011. in press .
51. Barete S, Assous N, de Gennes C, Grandpeix C, Feger F, Palmerini F, Dubreuil P, Arock M, Roux C, Launay JM, Fraitag S, Canioni D, Billefont B, Suarez F, Lanternier F, Lortholary O, Hermine O, Francès C. Systemic mastocytosis and bone involvement in a cohort of 75 patients. *Ann Rheum Dis*. 2010;**69**:1838–1841. doi: 10.1136/ard.2009.124511. [PubMed] [Cross Ref]
52. Molderings GJ, Solleder G, Kolck UW, Homann J, Schröder D, von Kügelgen I, Vorreuther R. Ureteral stones due to systemic mastocytosis: diagnostic and therapeutic characteristics. *Urol Res*. 2009;**37**:227–229. doi: 10.1007/s00240-009-0198-0. [PubMed] [Cross Ref]

Articles from *Journal of Hematology & Oncology* are provided here courtesy of
BioMed Central